Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy (BEMPENET)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Pasquale Perrone Filardi
- Phone Number: +39081/7462224
- Email: fpperron@unina.it
Study Locations
-
-
Napoli
-
Napoli, Napoli, Italy, 80131
- Recruiting
- Federico II University of Naples, Department of Advanced Biomedical Sciences
-
Contact:
- Pasquale Perrone Filardi
- Phone Number: +39081/7462224
- Email: fpperron@unina.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients under Bempedoic acid treatment
Exclusion Criteria:
- Age < 18 years o > 80 years
- Patients who refuse to participate and to sign informed consent
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Subjects with hyperlipidaemia under Bempedoic acid treatment
|
film-coated tablets
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Description of adherence to treatment with Bempedoic acid in a real-life Italian population
Time Frame: 6-12-24-36 months
|
Adherence will be assessed in terms of Medical Possession Ratio (MPR), which is defined as the ratio between the treatment units dispensed during the treatment period and the duration of the treatment period itself.
|
6-12-24-36 months
|
|
Description of efficacy of treatment with Bempedoic acid in a real-life Italian population
Time Frame: 6-12-24-36 months
|
Efficacy of treatment will be evaluated as a change in the LDL (deltaLDL) value from the start of treatment (percentage and absolute value).
|
6-12-24-36 months
|
|
Description of persistence to treatment with Bempedoic acid in a real-life Italian population
Time Frame: 6-12-24-36 months
|
Persistence will be assessed in terms of therapeutic continuity from the start of treatment to enrollment.
|
6-12-24-36 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Description of safety of treatment with Bempedoic acid in a real-life Italian population
Time Frame: 6-12-24-36 months
|
Safety will be evaluated in terms of adverse reactions or intolerance to the drug.
|
6-12-24-36 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Prot. 28/2025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.